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!ree-dimensional (3D) cell culture systems are rapidly developing1,2 because they re"ect in vivo characteristics 
better than conventional two-dimensional (2D) monolayer culture in regards to architecture, drug sensitivity3,4, 
gene expression, protein characteristics, and signal transduction5–7. For example, HER2 changes its dimerization 
partner from HER3 in 2D culture to HER2 in 3D culture, resulting in sensitivity to trastuzumab and intracellular 
signalling pathways8. On the other hand, primary culture systems are a more promising approach than established 
cell lines. A glioma study indicated that genomic pro#les are frequently altered from those of parental tumours 
during short-term 2D culture, but they are more stable and representative of parent tumours when cultured in 3D 
spheroids9. !erefore, spheroids cultured directly from tumours can best re"ect in vivo tumour characteristics.
We previously established an e$cient method for primary spheroid culture from patient tumours, the cancer 
tissue-originated spheroid (CTOS) method10. !e principle of the CTOS method is to maintain cell-cell con-
tact throughout the preparation and culture process. CTOS-derived xenotumours preserve the features of the 
patient tumours from which they originate. !ese characteristics of CTOSs promise more reproducible stud-
ies of patient tumours than cell lines. Loss of cell polarity is considered a hallmark of cancer11–13, but adeno-
carcinomas form gland-like structures, indicating that cell polarity is not completely lost, but retained to some 
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status in CTOS-derived xenotumours10. In colorectal CTOSs, the apical membrane forms on the spheroid sur-
face under "oating culture conditions (i.e., suspension culture), but it forms on the surface of the lumens inside 
gel-embedded CTOSs (Okuyama, Am J Pathol, in press).
Circulating tumour cells (CTCs) are regarded as an origin of cancer metastasis, and the presence of clusters of 
CTCs reportedly correlates with metastatic potential and worse prognosis than single CTCs14–16. In the region of 
microvessel invasion in CRC tumours, we found that some of the cancer cell clusters have the apical membrane 
on their surface (Okuyama, Am J Pathol, in press), which is quite similar to the CTOSs cultured under "oating 
conditions. !us, the adhesion of apical membrane protein can be a critical event for cell clusters in metastasis.
Phenotypic screening of new drug candidates is based on their e%ectiveness against phenotypes of the target dis-
ease. In contrast, targeted-based screening is based on the target molecule and the molecular mechanism of action 
for e%ective drugs. Phenotypic screening is more successful than targeted screening for #rst-in-class drugs17. As a 
large number of novel anti-cancer drugs are monoclonal antibodies, the generation of monoclonal antibodies using 
phenotypic screening is a promising approach18. Some studies have reported phenotypic screening for anti-cancer 
antibodies using phage display19–21 or hybridomas22, though they used cell lines or 2D cultured patient-derived cells.
In the present study, we aimed to generate antibodies by phenotypic screening using CTOSs, as colorectal CTOSs, 
which preserve the architecture of the in vivo tumour, may reproduce the protein localization and modi#cation. We 
selected the hybridoma approach because high a$nity antibodies can be expected23. We directly immunized mice 
with the CTOSs and obtained monoclonal antibodies that recognized molecules on the apical membrane, further 
screening them based on their inhibition of adhesion. We obtained a monoclonal antibody, 5G2, and the antigen was 
detected in various CTOSs, as well as original tumours, but not cell lines. We demonstrate that 5G2 recognizes the 
glycan structure of CEACAM5 and CEACAM6, and investigated the mechanisms underlying adhesion inhibition.
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nize molecules on the CTOS surface, we intraperitoneally injected colorectal CTOSs, C45, into a mouse without 
adjuvant, expecting to preserve the 3D structure. Generation of antibodies against the CTOS surface was mon-
itored in mouse serum by whole mount immunocytochemistry (ICC) without permeabilization a&er several 
boost injections (Fig. 1a). Spleen cells were then fused to myeloma cells to obtain hybridomas. !e culture media 
from each hybridoma was screened by whole mount ICC of CTOS without permeabilization, and 90 clones were 
selected as generating antibodies against molecules on the CTOS surface.
These 90 hybridoma clones were evaluated for their effect on the adhesion of CTOSs to the extracel-
lular matrix (ECM). Only clone 5G2 signi#cantly inhibited CTOS adhesion to type I collagen-coated dishes 
in a dose-dependent manner (Fig. 1a,b). Inhibition of adhesion was also detected in Matrigel or type IV 
collagen-coated dishes (Fig. S1). Limiting dilution was performed twice to clone the 5G2 monoclonal antibody 
(mAb) and the isotype of puri#ed antibody found to be IgG3κ . ICC with sectioned CTOSs revealed that the 
5G2 mAb signal co-localized with apical membrane marker ZO-1 on the surface of CTOSs under "oating condi-
tions and on the surface inside the lumen in gel-embedded culture (Fig. 1c). 5G2 signals were also detected on the 
lateral membrane or in the cytosol, but the signal intensity was lower than at the apical membrane. Growth was 
inhibited by pre-incubation with a relatively high dose (100 μg/ml) of 5G2 antibodies under Matrigel embedded 
conditions (Fig. 1d), but not under "oating conditions (Fig. 1e). !ese results indicate that 5G2 mAb mainly rec-
ognized molecules on the apical membrane of CTOSs and inhibited the adhesion of CTOSs to the ECM.
???? ?????????????????????????? ????????????????????????????????????? As 5G2 mAb inhibited the 
adhesion of CTOSs to the ECM, we further analysed the e%ect of 5G2 on cell adhesion and migration in detail. 
!e C45 CTOSs were cultured on type I collagen-coated dishes (C45-2D cells). When 5G2 mAb was added to 
con"uent C45-2D cells, cell detachment increased 6.9-fold at 100 μg/ml (Fig. 2a,b). !e cell detachment was not 
likely due to direct cell toxicity, as TUNEL-positive cells were restricted at the edge of the remaining cells, proba-
bly because these cells peeled o% when adjacent cell clusters detached (Fig. S2). In addition, detachment occurred 
as cell clusters rather than single cells, and the detached cell clusters eventually formed spheroids, indicating that 
5G2 mAb inhibited adhesion to the ECM but not cell-cell contact.
!e addition of 5G2 mAb also inhibited the migration of C45-2D cells (Fig. 2c) with a 65.5% decrease at 30 μg/
ml (Fig. 2d). !e promotion of cell detachment by the addition of 5G2 mAb indicated that blocking antigen 
molecules with 5G2 mAb disrupted already established adhesion. !e inhibition of migration also indicated that 
5G2 mAb inhibited novel adhesion formations consistent with adhesion inhibition.
???????????????????? ??????????????????????????????????????????????? To assess whether the 5G2 
antigen is expressed in other colorectal CTOSs and cell lines, the expression of 5G2 mAb antigen was analysed 
using 10 colorectal CTOS lines and 7 conventional cell lines. Many of the CTOS lines expressed 5G2 antigen at 
various levels (Fig. 3a), but most of the cell lines did not express 5G2 antigen at all (Fig. 3b). Only T84 cells, a 
relatively di%erentiated cell line, had weak signal; polarity-maintaining MDCK cells did not express 5G2 antigen. 
Di%erent expression levels in CTOSs and cell lines were not likely due to 2D or 3D culture conditions, because 
5G2 expression levels in T84 cells did not increase under 3D conditions, and the expression levels in C45 CTOSs 
rather increased under 2D than 3D conditions (Fig. 3b).
Immunohistochemical analysis of xenotumours derived from colorectal CTOS lines also showed expression 
of 5G2 antigen. !e 5G2 signal localized on the apical surface of the lumen at various levels (Fig. 3c). !ese results 
were consistent with the apical localization of the 5G2 signal in CTOSs cultured in vitro (Fig. 1c). !e signal was 
also observed inside the lumen, suggesting that antigen molecules on the apical membrane may be secreted or 
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Figure 1. Generation of monoclonal antibody against the CTOS surface. (a) Top, whole mount 
immunocytochemistry (ICC) without permeabilization of live CTOSs with 5G2 mAb. CTOSs were incubated 
with 1 μg/ml puri#ed 5G2 mAb or mouse IgG3κ isotype control and observed by confocal microscopy. Scale 
bar, 50 μm. Bottom, phase contrast images of an adhesion assay. CTOSs were cultured for 5 days with or 
without 5G2 hybridoma culture media on a type I collagen-coated dish. Scale bar, 100 μm. (b) Quanti#cation of 
adhesion to type I collagen-coated plates based on the percentage of adhered CTOSs. Data indicate mean ± SD 
from three independent experiments. Each condition was performed in triplicate and data are shown relative 
to the negative control (non-treated) in each experiment. Vehicle: 10% glycerol-PBS. Di%erences between 5G2 
and control IgG were analysed using ANOVA. (c) Immunohistochemistry of sectioned CTOSs with 5G2 mAb 
(green) and ZO-1 (red). CTOSs were cultured in "oating or gel embedded conditions. Gel embedded CTOSs 
were cultured for 3 days in type I collagen gel. Scale bar, 50 μm. (d,e) E%ect of pre-incubation with 5G2 mAb on 
CTOS growth under Matrigel embedded (d) or "oating (e) culture conditions. Growth of CTOSs was evaluated 
by the day 7 to day 0 size ratio and the data normalized to a mean of 0 μg/ml for each experiment. Values are 
relative to the negative control (non-treated). Statistical analysis was performed by the Kruskal-Wallis test. 
Horizontal bar: median; boxes: 25th and 75th percentiles; bars: 10th and 90th percentiles. Data are from more than 
three independent experiments. V, vehicle, 10% glycerol-PBS.
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shed into the lumen of the glandular structure. !us, the 5G2 antigen was widely detected in CRC CTOSs and 
their xenotumours, but hardly in many conventional cell lines.
???? ???????????????????????????????????? Western blotting with 5G2 mAb revealed broad and 
smeared bands, suggesting that the 5G2 antigen recognizes glycosylated molecules. To identify antigen proteins, 
the molecular weights of the antigen molecules without glycosylation were examined. Membrane-rich fractions 
of C45 were digested with N-glycosidase and/or neuraminidase. Surprisingly, the 5G2 signals disappeared a&er 
the digestion of N-glycan by N-glycosidase, and additional digestion of sialic acid by neuraminidase restored the 
signal (Fig. 4a). Single digestion by neuraminidase also increased 5G2 reactivity compared to the un-digested 
sample. No sharp bands caused by un-glycosylated protein appeared a&er the digestion of glycan. !ese results 
suggest that the 5G2 mAb recognizes the N-glycan moiety and modi#cation with sialic acid inhibits 5G2 recog-
nition. !e intense signal with double digestion of N-glycosidase and neuraminidase indicated that the masked 
antigen by sialic acids was abundant in C45 CTOSs. !e intensity of the signal was compatible with or without 
N-glycosidase treatment, indicating that the masked antigen was mainly on O-glycan. !e size of the bands 
treated with double digestion was smaller than that with neuraminidase single digestion, probably because the 
masked antigen on N-glycan was lost by N-glycosidase treatment.
To con#rm that 5G2 recognized N-glycan, C45 CTOSs and C45-2D cells were treated with tunicamycin, an 
























































Figure 2. 5G2 mAb promoted C45-2D cell detachment and inhibited cell migration on collagen-coated 
dishes. (a) Cresyl violet staining of C45-2D cells. Con"uent C45-2D cells were incubated with 5G2 mAb for  
3 days. Scale bar, 100 μm. (b) Quanti#cation of cell detachment areas when treated with the indicated 
antibodies. Data indicate mean ± SD from three independent experiments. Di%erences were analysed by  
the Kruskal-Wallis test. (c) Quanti#cation of cell migration. C45-2D cell migration was assessed by the 
percentage of closure a&er 3 days in culture a&er removal of the culture insert and antibody addition. Data 
indicate mean ± SD from four independent experiments. Di%erences were analysed by the Kruskal-Wallis test. 
(d) Representative images of the cell migration assay in (c). !e antibody doses were 30 μg/ml. !e white dotted 
lines indicate the edge of the space. Scale bar, 100 μm.
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signal was observed in relatively low dose (1μg/ml), although it is still possible that the decrease was also due to 
general suppression of protein synthesis by tunicamycin.
Various CTOSs and cell lines were analysed for their reactivity to 5G2 mAb with neuraminidase digestion. All 
of the CTOS lines had more intense 5G2 signals than the undigested samples, even if it was not detected without 
neuraminidase digestion, as in CB3 and C111 (Fig. 4c). !e 5G2 signal appeared a&er neuraminidase digestion 
in the HT29 and DLD-1 cell lines, but not the Caco-2 and HCT116 cell lines (Fig. 4d). !ese results suggest that 
5G2 antigen glycan was commonly further modi#ed with sialic acid, and the modi#cation inhibited recognition 
by 5G2.
The glycan binding property of 5G2 mAb was investigated using a glycan microarray. The 5G2 mAb 
recognized the Lea (Galβ 1-3(Fucα 1-2)GlcNAc), Lec (Galβ 1-3GlcNAc), core1 (Galβ 1-3GalNAc), core2 
(Galβ 1-3(GlcNAcβ 1-6)GalNAc), and Siaα 2-6core1 (Siaα 2-6(Galβ 1-3)GalNAc) structures (Fig. 4e, 
Supplementary Table S1). Core1, core2, and Siaα 2-6Core1 were O-glycan-speci#c structures. On the other hand, 
both N-glycan and O-glycan could be modi#ed by Lea and Lec. Furthermore, sialy-Lea and sialy-Lec were not 
detected by 5G2 mAb, con#rming that the 5G2 mAb speci#cally recognized non-sialylated, asialo-type Lea and Lec. 
!ese results suggest that the main antigens of 5G2 mAb were the Lea and Lec structures on N-glycan in CTOSs, 
and 5G2 mAb recognizes Galβ 1-3GlcNAc/GalNAc as a minimum recognition epitope. Lea and Lec could exist on 
various glycan structures. Consistently, broad smear was observed in long exposure of Western blotting of C45 
lysate with 5G2 mAb. Meanwhile, the 5G2 mAb revealed two intense bands in short exposure (Fig. S3). !erefore, 
C45 could express two major carrier glycoproteins modi#ed with glycans containing the Galβ 1-3GlcNAc/GalNAc 
epitope, such as Lea and Lec, without further modi#cation with sialic acid.
???? ?????????????? ?? ??? ??? ???? ??????????? ???????? !e membrane-concentrated frac-
tion of C45 was immunoprecipitated with the 5G2 mAb and then subjected to mass spectrometry analysis a&er 
SDS-PAGE. Lysate from HCT116 cells was used as a negative control. Several candidate proteins were selected 
based on peptides in the immunoprecipitates of C45 with 5G2 mAb but not negative control IgG. Peptides in 
Figure 3. Expression of 5G2 mAb antigen in colorectal cancer-derived CTOSs and cell lines.  
(a,b) Western blot of lysate from colorectal cancer-derived CTOSs (a) and cell lines (b) using 5G2 mAb.  
(c) Immunohistochemical analysis of CTOS-derived xenotumour with 5G2 mAb. Scale bar, 100 μm.
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HCT116 cells were excluded. Furthermore, candidate proteins were narrowed down based on higher expression 
levels in C45 than HT29 in microarray analysis (Supplementary Table S2).
For these candidates, 5G2 reactivity was examined using each siRNA in C45 CTOSs. 5G2 reactivity dramati-
cally decreased when the expression of two of the candidates, CEACAM5 (known as CEA) and CEACAM6, was 
substantially repressed by siRNA (Fig. 5a). Further con#rmation was obtained with over-expression of HA-tagged 
CEACAM5 and CEACAM6 in T84 cells, which had endogenously low but detectable 5G2 reactivity. HA-tagged 
CEACAM5 and CEACAM6 were immunoprecipitated and detected with 5G2 mAb, indicating that they con-
tain the glycan structure recognized by 5G2. Antibodies against HA, CEACAM5, or CEACAM6 detected two 
Figure 4. 5G2 mAb recognized asialo-type N-glycan structure. (a) Western blot of glycosidase digested 
membrane fractions of C45 CTOSs using 5G2 mAb. (b) Western blot of lysate from tunicamycin-treated cells 
using 5G2 mAb. C45 CTOSs and C45-2D cells were cultured with the indicated doses of tunicamycin for 2 
days. (c,d) Western blot of sialic acid-digested cell lysate using 5G2 mAb. Protein lysates from CTOSs (c) and 
cell lines (d) were digested by neuraminidase. Actin is shown as a loading control. (e) Glycan microarray for 




major bands, whereas 5G2 mAb detected only upper bands, indicating that recognition by 5G2 mAb required 
full glycan modi#cations (Fig. 5b). !ese results suggest that the 5G2 mAb mainly recognized the N-glycans on 
CEACAM5 and CEACAM6. However, the expression levels of CEACAM5 and CEACAM6 detected by each 
speci#c antibody did not correspond to those detected by 5G2 in CTOS lines (Fig. 5c), suggesting that only a 
part of CEACAM5 and CEACAM6 have the N-glycan modi#cation recognized by 5G2 mAb. !e expression 
levels of CEACAM5 and CEACAM6 were lower in cell lines than in CTOSs, which is consistent with their lower 
reactivity to 5G2 mAb (Fig. S4). Furthermore, hierarchical clustering analysis using microarray data revealed that 
expression levels of glycosylation-related enzymes in CTOSs were closely related to each other as well as their 
tumours of origin, but not cell lines (Fig. S5). !us, not only CEACAM expression, but also the expression pro#le 
of glycosylation-related enzymes di%ered between CTOSs and cell lines.
Immunohistochemical analysis of patient samples revealed that the 5G2 mAb signal was mostly matched with 
CEACAM5, CEACAM6, or both (Fig. 6). Similar results were observed in CTOS lines (Fig. S6). !e 5G2 signal 
predominantly localized inside the cells rather than on the apical membrane in the normal colon (Fig. 6a). !e 
5G2 signal was also more predominant on the apical membrane and inside the lumen in patient tumours similar 
to CTOSs-derived xenotumours (Fig. 3c) compared to the CEACAM5 and CEACAM6 signal (Fig. 6b). !e 5G2 
signal preferentially co-localized with CEACAM6 at the invasive front of the C48 tumour (Fig. 6c). !ese results 
suggest that 5G2 mAb recognized the N-glycan on CEACAM5 and CEACAM6, which had a more secretory or 
invasion-related nature in tumours.
???? ??????????????????????????????????????????????????? Next, we investigated the mechanism 
underlying 5G2 mAb inhibition of spheroid adhesion and the detachment of 2D cultured C45 CTOSs from 
collagen-coated dishes. Integrins are major ECM receptors. Microarray analysis revealed that, in C45, the expres-
sion levels of integrin β 4 and α 6 were higher than other integrin family members. !erefore, we focused on 
the relationship between 5G2 mAb and integrin β 4. ICC revealed that integrin β 4 localized mainly at the lat-
eral membrane under "oating conditions (Fig. 7a). When CTOSs were embedded in gel, integrin β 4 translo-
cated to the outer surface, which is the ECM interface, but treatment with 5G2 suppressed the translocation 
(Fig. 7a). Quantitative analysis of integrin β 4 localization revealed that the average percent coverage of integrin 
Figure 5. CEACAM5 and CEACAM6 were major carriers of 5G2 antigens. (a) Western blot of lysate from 
siRNA-transduced C45 CTOSs using the indicated antibodies. Actin is shown as a loading control.  
(b) Western blot of lysate from T84 cells in which HA-tagged CEACAM5 and CEACAM6 were forcibly 
expressed. Cell lysates were immunoprecipitated by HA antibody and detected by HA, CECAM5, CEACAM6, 
or 5G2 antibodies. !e two major bands are indicated by arrowheads. (c) Western blot of lysate from colorectal 
cancer CTOS lines with CEACAM5, CEACAM6, and 5G2 antibodies. Actin is shown as a loading control.
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β 4 on the outer CTOS surface 20 h a&er Matrigel embedding signi#cantly decreased from 70.6% (control IgG 
pre-incubation) to 50.8% with 5G2 pre-incubation (Fig. 7b). Furthermore, the intensity of integrin β 4 signals on 
the lateral membrane was signi#cantly greater in 5G2 pre-incubated CTOSs than in IgG pre-incubated CTOSs 
(Fig. 7c). !ese results suggest that 5G2 mAb impairs the translocation of integrin β 4 from the lateral membrane 
to the ECM contact interface. Integrin binding with the ECM induces the phosphorylation of focal adhesion 
kinase (FAK)24. We found that FAK phosphorylation increased 6 h a&er Matrigel embedding, and 5G2 mAb 
pre-incubation suppressed FAK phosphorylation (Fig. 7d).
To con#rm whether the inhibition of the integrin signal is due to direct interaction between CEACAMs and 
integrin β 4, immunoprecipitation was carried out (Fig. 7e). Integrin β 4 did not co-immunoprecipitate with 
CEACAM5 or CEACAM6, and neither CEACAM5 nor CEACAM6 co-immunoprecipitated with integrin β 4, 
suggesting that CEACAM5 and CEACAM6 do not directly associate with integrin β 4. In addition, 5G2 mAb did 
Figure 6. Localization of 5G2 antigen is consistent with CEACAM5 and CEACAM6 in patient tissues.  
(a) Immunohistochemical analysis of human normal colon and (b,c) tumour sections from patient tumours 
stained with CEACAM5, CEACAM6, and 5G2 antibodies as indicated. (c) High magni#cations of the invasive 
front region of C48. Scale bar, 100 μm (a,c), 200 μm (b).
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Figure 7. Pre-incubation with 5G2 mAb inhibited translocation of integrin β 4 in CTOSs.  
(a) Immunocytochemical analysis of CTOSs using integrin β 4 antibody. C45 CTOSs under "oating  
conditions (i.e., suspension culture) were pre-incubated with the indicated antibody and cultured for 20 h in 
Matrigel. (b) CTOS surface coverage with the integrin β 4 signal. C45 CTOSs were treated the same as in  
(a). Di%erences were analysed by the Mann Whitney U-test. IgG, n = 111; 5G2, n = 139. Horizontal bar, 
median; boxes, 25th and 75th percentiles; bars, 10th and 90th percentiles. (c) Integrin β 4 signal intensity on lateral 
membranes in CTOSs. C45 CTOSs were treated the same as in (a). Data indicate mean ± SD. Di%erences were 
analysed by the Mann Whitney U-test. IgG, n = 1512; 5G2, n = 2066. (d) Western blot using phosphor-FAK 
(pFAK) or total FAK (tFAK) antibody. C45 CTOSs in "oating conditions (F) were pre-incubated with the 
indicated antibody and cultured for 6 h in Matrigel (G). (e) Immunoprecipitation analysis of "oating cultured 
C45 CTOSs. Antibodies used for immunoprecipitation (IP) and detection (Blot) are shown.
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!ese results suggest that pre-incubation with 5G2 mAb inhibited integrin signalling, probably through an 
attenuation of the translocation of integrin β 4 from the lateral membrane to the ECM interface without direct 
interaction between CEACAM5 or CEACAM6 and integrin β 4.
L'8,988'(#
!e CTOS is a culture system that preserves in vivo tumour characteristics. In this study, we generated monoclo-
nal antibodies against the surface of CTOSs and identi#ed a monoclonal antibody, clone 5G2, that inhibits CTOS 
adhesion to the ECM. We demonstrated that the antibody recognizes N-glycan structures, including Lea and Lec. 
Major carrier proteins with these glycan structures are CEACAM5 and CEACAM6, which are over-expressed in 
CRC.
Most of the proteins have post-translational glycan modi#cations. Glycosylation is known to play roles in the 
regulation of cell motility, cell adhesion, and receptor activation of malignant cells25. Aberrant glycosylation is 
o&en observed on the surface of tumour cells26–28, and many tumour markers in clinical use are antibodies against 
glycans27. Recent glycomics studies have elucidated that cancer-speci#c structures and abnormal glycan distribu-
tion can be novel biomarkers of cancer26,29. However, it is di$cult to reproduce glycan structures in vitro in con-
ventional cell lines because glycan structures are prone to being a%ected by many factors, such as the expression 
levels of substrate proteins and glycosyltransferases and function of the Golgi apparatus25,30.
We previously reported that CTOS maintain the morphology of their original tumours10. Here we demon-
strated that CTOS also maintain the glycan structures of their original tumours. Antigens of 5G2 mAb were 
glycans highly expressed in CTOSs similar to patient tumours, but 2D-cultured cell lines expressed low levels of 
the antigens. Even 2D-cultured CTOS-derived cells, C45-2D cells, exhibited altered patterns on Western blots 
with 5G2 mAb. !ese results suggest that glycosylation patterns or protein expression can quickly change under 
2D culture conditions. As studies of glycans in tumours mostly depend on limited patient samples, evaluating a 
small amount of glycan structure is di$cult, but we demonstrated that CTOS can be a novel platform for studying 
tumour glycans.
Immunohistochemical analysis of patient samples revealed that, in normal regions, 5G2 signals are observed 
mainly inside cells, whereas CEACAM signals localize on the membrane. In contrast, in tumour regions, 5G2 sig-
nals decrease inside cells but increase on the apical membrane and accumulate in the lumen, whereas CEACAM 
signals occur on the membrane and in the cytosol. !e discrepant localization of 5G2 and CEACAM signals may 
be due to the 5G2 antigen being an immature form of the glycosylation on CEACAMs, which may not be trans-
ported to the apical membrane and remain inside the cell compartments, such as Golgi, in normal cells. In cancer 
cells, the protein transport system may be disturbed so that CEACAMs with 5G2 antigen glycan can be localized 
at the membrane and secreted into the lumen. !e di%erent pattern of localization of 5G2 and CEACAM signals 
in normal and tumour tissue suggests that 5G2 mAb could be a more tumour-speci#c marker, though further 
analysis is required.
Sialylation is enhanced in cancer cells26. CA19-9, one of the CRC tumour markers, recognizes sialyl-Lea 26. 
A small amount of Lea and Lec was previously reported to exist on CEA31. In this study, the asialo-type 5G2 
antigen glycans on CEACAMs were also minor structures, as neuraminidase digestion signi#cantly increased 
5G2 reactivity. Asialo-type 5G2 antigen was highly expressed in CRC, probably because the expression levels 
of CEA proteins are increased, as well as N-glycosylation on CEA32. In-depth N-glycan pro#ling indicates that 
α 2,3-sialylation is down-regulated in CRC tumours relative to non-tumorigenic tissues33; therefore, tumour cells 
may have incomplete α 2,3-sialylated glycans of CEA, such as asialo-type 5G2 mAb antigen. In addition, a func-
tional monoclonal antibody recognizing such minor glycan structures was generated, suggesting that 5G2 antigen 
glycan locates to an easily accessible CTOS surface for immune cells and the antibody.
Detailed analysis of the sialylation e%ect by the modi#cation of speci#c sites on the glycan structure is di$cult 
because CEACAM5 has 28 N-glycosylation sites, and neuraminidase digestion or neuraminidase mutant cells 
also a%ect other protein glycans. !e CEACAM family consists of 22 di%erent genes, including 12 CEACAM 
subgroup genes and 10 pregnancy-speci#c glycoproteins (PSG). !e amino acid sequences reveal homology in 
the immunoglobulin (Ig) variable-like domain (IgV-like) and Ig constant C2-like domain (IgC2-like) among 
their extracellular domains34–36, suggesting that other minor CEA proteins can also be modi#ed with 5G2 anti-
gen glycan. In addition, as the core glycan structure of 5G2 recognition was revealed to be Galβ 1-3GlcNAc/
GalNAc according to the glycan array analysis, we do not exclude the possibility that the antigens are not speci#c 
to CEACAM5 and 6. !us, detailed characterization of the role of 5G2 antigen glycan requires further analysis.
CTOSs may be able to metastasize because they resemble CTC clusters, which are highly associated with 
metastatic potential14–16. Recently, we reported that colorectal CTOSs have an apical membrane on the outer 
surface of the spheroid when cultured under "oating conditions, and the polarity promptly switches when they 
are embedded in the ECM, forming lumens surrounded by the apical membrane inside the spheroids (Okuyama, 
Am J Pathol, in press). In the region of microvessel invasion in patient tumours, some of the cell clusters are sur-
rounded by an apical membrane, indicating that "oating CTOS-like cell clusters can be an origin of metastasis. 
In this scenario, the #rst step at the metastasis site is contact between the apical membrane and the vessel surface, 
and then invasion of the ECM and polarity switching to form metastatic foci that have the same polarity status as 
the original tumours. !e process of "oating spheroids becoming monolayer cells mimics the metastatic process, 
including migration, invasiveness, chemoresistance, and expression of cancer stem cell markers37,38. As 5G2 mAb 
inhibited the adhesion of "oating CTOSs to the ECM, the antibody may have the ability to inhibit metastasis.
We showed that pre-incubation of the spheroids with 5G2 impaired translocation of integrin β 4 from the 
lateral membrane to the contact interface between the extracellular matrix when embedded in it. As the integrin 
is known to play critical role on cell adhesion to extracellular matrix, the impairment of the integrin β 4 trans-
location is likely to be involved in the adhesion inhibition, although the detailed mechanism remains unclear. 
Overexpression of CEACAM5 and CEACAM6 reportedly increase the binding ability of integrin α 5β 1 to 
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#bronectin39. Heterodimerization of CEACAMs by crosslinking with antibody enhances the adhesion of neutro-
phils to #bronectin, accompanied by increased localization of Src family kinase to the cytoskeleton and increases 
their kinase activity40, and antibody-mediated crosslinking of CEACAM6 induces resistance to anoikis through 
Src-mediated FAK phosphorylation in a caveolin-1-dependent manner41. Taken together, these reports suggest 
that clustering via the extracellular domains of GPI-anchor type CEACAM5 and CEACAM6 regulates adhesion 
to the ECM through integrin signalling. 5G2 mAb may inhibit the clustering by recognizing N-glycan on the 
extracellular domain of CEACAM5 and CEACAM6, inhibiting adhesion to the ECM and delaying integrin trans-
location to the ECM contact interface, resulting in reduced FAK phosphorylation.
Although we focused on the 5G2 clone in detail in this study, we also obtained many other antibod-
ies that recognize the CTOS surface and may be antibody-mediated drugs targeting CTC clusters, as the 
existence of apical membrane inside the vessel is abnormal. As the ability of the antibodies to internalize 
is critical for antibody-mediated targeting42,43, further screening by internalization may be useful for #nding 
antibody-mediated drug candidates. In the case of the antigen proteins being secreted or shed from the apical 
membrane, they can be tumour markers.
7"&3(/8
!"#"$%&'(#)(*)+(#(,-(#%-)%#&'.(/'"8G) C45 CTOSs were washed and suspended in HBSS (GIBCO). A 
10-week-old female Balb/c mouse (CLEA Japan, Inc., Tokyo, Japan) was immunized by intraperitoneally injecting 
1–2.5 × 104 CTOSs. A boost injection was performed eight times at 1-week intervals. !ree days a&er the #nal 
boost injection, spleen cells were harvested and fused to mouse myeloma cells (P3-X63Ag8.653) using polyethyl-
ene glycol (Sigma, St. Louis, MO). !e fused cells were cultured with CM-B medium (EIDIA, Tokyo, Japan) and 
hybridoma cells selected by HAT selection. Clone 5G2 was cloned by limiting dilution (twice) and expanded with 
SF-B medium (EIDIA). Antibody was puri#ed using the MAbTrap kit (GE Healthcare, Buckinghamshire, UK). 
!e immunoglobulin class was determined using the IsoStrip mouse monoclonal antibody isotyping kit (Roche 
Diagnostics GmbH, Mannheim, Germany).
4AC=);$";%$%&'(#)%#/),"--),9-&9$"G) !e collection, handling, and use of human tumour tissue samples 
were performed in accordance with protocols approved by the institutional ethics committees at Osaka Medical 
Center for Cancer and Cardiovascular Diseases. Human tissue samples were obtained a&er informed consent. All 
animal work was performed according to the protocols approved by the institutional animal study committee of 
Osaka Medical Center for Cancer and Cardiovascular Diseases. CTOSs were prepared and cultured according 
to a previously described protocol10. Brie"y, CTOS-derived xenogra& tumours were dissected from immuno-
de#cient mice. A&er mechanical dissociation, tumour fragments were digested with Liberase (Roche) for 2 h at 
37 °C. Cell clusters ranging in size from 40 μm to 250 μm were collected by #ltration with steel wire mesh and 
cell strainers (Falcon, Corning, NY). Collected cell clusters were cultured in StemPro hESC (GICO, Waltham, 
MA) and maintained under "oating culture conditions. Cell lines were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). T84 cells were cultured in DMEM/F12 (GIBCO), HT29 cells and HCT116 
cells in MacCoy’s 5a medium (GIBCO), DLD-1 cells in RPMI1640 medium (GIBCO), and Caco-2 cells and 
MDCK cells in MEM (GIBCO) with 0.1 mM NEAA (GIBCO), each supplemented with 10% FBS. C45-2D cells 
were established from C45 CTOSs (colorectal cancer-derived). CTOSs were digested with trypsin, plated in type 
I collagen-coated dishes, and cultured in DMEM/F12 supplemented with 10% FBS.
6/3"8'(#)%88%0G) Approximately 100 CTOSs were incubated with hybridoma-cultured media or puri#ed 
antibody at 37 °C for 3 h, and then plated in 96-well tissue culture plates (IWAKI Shizuoka, Japan) coated with 
type I collagen (Nitta Gelatin Inc., Osaka, Japan). !e total number of and number of adhered COTSs were 
counted on day 0 and day 2, respectively.
L"&%,3+"#&)%88%0G) C45-2D cells were cultured on collagen-coated 96-well culture plates until reaching 
con"uence. Antibodies were added to the cells and cultured for 3 days. Cells were #xed with 4% PFA and stained 
with cresyl violet. !ree independent #eld images were taken of one well and the cell-free area measured by 
ImageJ (National Institutes of Health, Bethesda, MD). !e experiments were performed in triplicate and repeated 
three times.
7'1$%&'(#)%88%0G) C45-2D cells were cultured on type I collagen-coated 8-well μ-slide with culture-insert 
(ibidi, Martinsried, Germany). A&er cells reached con"uence, the insert was removed and the medium changed 
to 1% FBS containing DMEM/F12 with antibodies, and then cultured 3 more days. Photos were taken upon the 
removal of the insert and a&er 3 days in culture. Four photos were taken of one well. !e cell-free area was meas-
ured by ImageJ. !e experiments were repeated four times. !e percentage of coverage equals the cell-free area 
on day 3/cell-free area on day 0 × 100.
!$(F&3)%88%0G) CTOSs 40–70 μm in size 5 to 8 days a&er preparation from xenogra&s were pre-incubated 
with antibodies at 37 °C overnight. !e CTOSs were then transferred to a well on a 96-well plate and cultured for 
1 week under "oating or Matrigel (GIBCO) embedded conditions. Photos were taken with phase contrast micros-
copy and CTOS size measured by ImageJ. Growth was evaluated based on the day 7 to day 0 size ratio.
E++9#(3'8&(,3"+',%-)%#%-08'8G) CTOSs were #xed with formaldehyde and then embedded in paraf-
#n. Para$n sections (4 μm) were depara$nized and antigen retrieval performed in 10 mM citrate bu%er (pH 
6.0) for 15 min at 121 °C. A&er blocking with 10% normal goat serum in PBS containing 0.1% Triton X-100 
(PBS-TX), the sections were incubated with primary antibodies in 5% goat serum in PBS-TX at 4 °C overnight. 
For immunoperoxidase detection, the sections were incubated with biotin-conjugated secondary antibody 
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(Vector Lab, Burlingame, CA), labelled using the VECTASTAIN Elite ABC kit (Vector), and visualized with 
NovaRED (Vector). For immuno"uorescent detection, Alexa Fluoro 488- and 594-conjugated secondary anti-
body (Molecular Probes) was used. For integrin β 4 staining, antigen retrieval was performed by treatment with 
20 μg/ml proteinase K in 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 0.1% Triton for 15 min at room tem-
perature. A&er mounting with ProLong Gold antifade mountant with DAPI (Molecular Probes), images were 
obtained using a BX50 microscope (Olympus, Tokyo, Japan) with a DP73 CCD camera or confocal microscope 
(TCS SPE; Leica Microsystems, Wetzlar, Germany).
I3(-")+(9#&)'++9#(,0&(,3"+'8&$0)(*)4AC=8G) C45 CTOSs were washed with 0.5% BSA in PBS 
and blocked with 1% BSA in PBS at room temperature for 15 min. The CTOSs were then incubated with 
hybridoma-cultured media at room temperature for 1 h. A&er washing three times, CTOSs were incubated with 
Alexa488-conjugated anti-mouse IgG (Molecular Probes, Waltham, MA) and Hoechst33342 (Molecular Probes) 
at room temperature for 1 h. Fluorescence images were captured using confocal microscopy.
6#&'.(/'"8G) Antibodies against ZO-1 were purchased from Invitrogen; CEACAM5 from Abcam (Cambridge, UK); 
CEACAM6 from Santa Cruz Biotechnology (Dallas, TX); β -actin from Sigma; phosphor-FAK from Invitrogen; FAK 
from BD Bioscience (San Jose, CA); and integrin β 4 from Novous Biological (Littleton, CO).
I"8&"$#).-(&&'#1G) CTOSs were lysed with RIPA bu%er (10 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM 
NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing EDTA-free complete proteinase inhibitor 
(Roche) and PhosSTOP phosphatase inhibitor (Roche) at 4 °C. A&er sonication and centrifugation, the superna-
tant was collected. !e protein concentration was measured using the BCA protein assay kit (Pierce, Waltham, 
MA). Basically, 10 μg of protein for detection of phosphorylation, 20 μg of protein was applied to one lane. A&er 
electrophoresis and blotting, the blots were blocked with 5% BSA in TBS-T (20 mM Tris-HCl pH 7.6, 150 mM 
NaCl, 0.1% Tween-20) at room temperature, and then incubated with primary antibody in TBS-T containing 
1% BSA overnight at 4 °C. A&er washing with TBS-T, the blots were incubated with HRP-conjugated secondary 
antibody (Santa Cruz) in TBS-T containing 5% (w/v) skim milk for 1 h at room temperature. A&er washing with 
TBS-T, signal was detected using ECL Prime Western blotting detection reagent (GE Healthcare) with an LAS-
4000mini (GE Healthcare).
E++9#(;$",';'&%&'(#G) Cells or CTOSs were homogenized and lysed with TNE-T bu%er (10 mM Tris-HCl 
pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Triton) containing EDTA-free complete proteinase inhibitor (Roche) at 
4 °C. A&er centrifugation at 14,000 rpm for 15 min at 4 °C, the supernatant was collected. A&er pre-clearing with 
protein G sepharose (GE Healthcare) for 1 h at 4 °C, the lysate was incubated with antibodies at 4 °C overnight, 
and then the antibodies collected by incubation with protein G sepharose. A&er washing with TNE-T bu%er, 
immunoprecipitated proteins were eluted by heating in 2x SDS-PAGE sample bu%er.
!-0,%#)%#%-08'8G) Glycosylation was digested according to the protocol provided by the manufacturer of gly-
cosidase enzymes. Brie"y, protein samples were incubated in glycoprotein denaturing bu%er with protease inhib-
itor cocktail at 100 °C for 10 min before treatment with glycosidase. N-glycosidase F (NEB, Ipswich, MA) and 
neuraminidase (NEB) were added to the denatured proteins and incubated at 37 °C overnight. N-glycan synthesis 
was inhibited by tunicamycin (Sigma). Glycan array analysis was performed according as described previously44. 
Brie"y, 5G2 mAb was pre-complexed with Cy3-labelled anti-mouse IgG antibody and then applied to the glycan 
array at 10μg/ml. Fluorescent images were acquired using an evanescent #eld-activated "uorescent scanner.
????????????????????????? ?????????????????? CEACAM5 and CEACAM6 cDNAs prepared from C45 
CTOSs were ampli#ed by PCR and the PCR products cloned into the TOPO cloning system (Invitrogen). A&er 
sequencing, the cDNAs were transferred to pCAGGS and 3x HA tag sequences inserted downstream of the sig-
nal sequence. Plasmid constructs were transfected into cells using X-tremeGENE HP DNA transfection reagent 
(Roche). For RNAi experiments, C45 CTOSs were incubated with 5 mM EDTA/PBS for 30 min at room temper-
ature, followed by transduction of 150 pmole of Silencer select siRNAs (ABI, Waltham, MA) into 5000 CTOSs 
(40–70 μm) using a NEPA21 electroporator (Nepa Gene, Chiba, Japan). !ree days a&er transduction of siRNAs, 
CTOSs were harvested and subjected to Western blotting.
=&%&'8&',%-)%#%-08'8G) Di%erences between two groups were analysed by a two-tailed Mann Whitney U test 
for non-parametric data, and more than three groups were analysed by the ANOVA test for parametric data or 
Kruskal-Wallis test for non-parametric data. Each di%erence was determined by Tukey’s multiple comparison 
test for parametric data or Dunn’s multiple comparison test for non-parametric data. Statistical analyses were 
performed using GraphPad Prism 6 (GraphPad So&ware, San Diego, CA).
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